Stemtech Corporation reported a significant decline in financial performance for the fiscal year ending December 31, 2025, with net sales totaling $2.88 million, down from $5.05 million in 2024, marking a decrease of approximately 43%. This decline was attributed primarily to stock-outs and supply disruptions affecting high-demand product lines, which limited distributor fulfillment. Despite maintaining a positive inventory balance of $217,338 at year-end, the company faced working capital constraints that hindered its ability to replenish stock effectively. Operating expenses also decreased to $5.02 million from $6.11 million, reflecting reduced operational activity in line with lower revenues.
The company reported a net loss of $4.05 million for 2025, compared to a net loss of $3.77 million in the previous year. This increase in net loss was largely due to the drop in revenue and the absence of a gain on extinguishment of debt that had positively impacted the prior year's results. Interest expenses decreased slightly to $1.45 million from $1.58 million, reflecting improved debt management. The total stockholders' deficit increased to $7.70 million, up from $5.23 million in 2024, primarily due to the net loss incurred during the year.
Strategically, Stemtech has focused on expanding its product offerings and enhancing its market presence. In December 2022, the company launched the Cellect One® Rapid Renew Stem Cell Peptide Night Cream, and in January 2025, it introduced the Cellect One® Shield HOCL skin care product. Additionally, the company plans to launch StemPets™, a pet supplement, in April 2025, tapping into the $303 billion global pet industry. The company aims to increase its Independent Business Partner (IBP) count by 30,000 over the next 12 to 24 months, enhancing its sales force and reducing customer acquisition costs.
Operationally, Stemtech's current assets decreased to $457,062 from $921,746 in 2024, primarily due to a reduction in accounts receivable and prepaid expenses. Current liabilities rose to $10.85 million from $9.01 million, driven by higher accounts payable and notes payable. The company has not generated positive cash flows from operating activities, with net cash used in operations amounting to $483,583 for 2025. The company continues to rely on financing activities, including proceeds from notes payable and factoring arrangements, to support its liquidity needs.
Looking ahead, Stemtech's management acknowledges the need for additional capital to sustain operations and support growth initiatives. The company plans to fund its operations through a combination of equity issuances, convertible debt, and short-term loans from directors. However, the reliance on external financing poses risks, as future funding is subject to market conditions and lender discretion. The company has expressed a commitment to improving product availability and addressing operational challenges to enhance revenue generation in the coming fiscal periods.
About Stemtech Corp
Stemtech Corporation develops science-based stem cell enhancement products and dietary supplements aimed at supporting natural body renewal and anti-aging. Its core offerings include stem cell activation formulas, oral health products, skincare, and pet supplements. Operating globally through a network marketing model, the company leverages independent distributors to expand market reach, emphasizing natural, clinically supported ingredients and a direct-to-consumer approach.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.